Folgen

  • (Part 2) The Neural Implant & BCI Industry Landscape
    Jul 6 2026

    In this episode we analyze the Industry Landscape of BCI Implants. The section closes with a strategic framework for how to think about market sizing, investment, and what it actually takes to build a durable business in one of the most capital-intensive and regulatory-complex sectors in all of technology.

    Key Topics:

    1. The Industry Overview
    2. The Technology Landscape
    3. The Major Players - Top Three
    4. Operational Realities
    5. Competitive Dynamics & How to Win
    6. Building an Ecosystem
    7. The Global Picture

    -------------------------------------------------------------

    Additional Notes and References:

    • Neuralink N1 chip — 1,024 electrodes; first human implant January 2024 → NPR, Fierce Biotech, Axis Intelligence
    • Synchron Stentrode — backed by Gates & Bezos ($75M Series C); COMMAND study positive 12-month results → CNBC, BusinessWire, Clinical Trials Arena
    • Precision Neuroscience — $102M Series C (Dec 2024); thin-film subdural array → Globe Newswire, Wikipedia, Nature Biomedical Engineering
    • BrainGate — NIH/DARPA funded, Brown University → BrainGate.org, Brown University News
    • Meta/Ctrl-Labs — $500M–$1B acquisition (2019); EMG wristband → Engadget, Neurofounders
    • EPFL / Prof. Courtine — brain-spine interface restoring walking (published in Nature) → EPFL, CHUV
    • China 14th Five-Year Plan, seven-ministry BCI policy (2025) → Chinese government website, MIT Technology Review, CSET Georgetown, Ofek Technology


    Any claims that could not be verified with real public sources (certain revenue figures, MindMaze funding details, Russia's Kurchatov Institute BCI output) are flagged.

    -------------------------------------------------------------Acronyms:

    ADHD - Attention Deficit Hyperactivity DisorderAI - Artificial IntelligenceALS - Amyotrophic Lateral SclerosisAR - Augmented RealityASIC - Application-Specific Integrated CircuitBCI - Brain-Computer InterfaceBMBF - Bundesministerium für Bildung und ForschungBRAIN - Brain Research Through Advancing Innovative NeurotechnologiesCE - Conformité EuropéenneCIHR - Canadian Institutes of Health ResearchCMS - Centers for Medicare & Medicaid ServicesCOVID - Coronavirus DiseaseDARPA - Defense Advanced Research Projects AgencyDBS - Deep Brain StimulationEEG - ElectroencephalographyEHR - Electronic Health RecordEMG - ElectromyographyEPFL - École Polytechnique Fédérale de LausanneEU - European UnionFDA - Food and Drug AdministrationGDPR - General Data Protection RegulationIDE - Investigational Device ExemptionIP - Intellectual PropertyISO - International Organization for StandardizationITMO - Institute of Technology, Mechanics and OpticsMDR - Medical Device RegulationMS - Multiple SclerosisNIH - National Institutes of HealthNMPA - National Medical Products AdministrationNSERC - Natural Sciences and Engineering Research Council of CanadaNSF - National Science FoundationOCD - Obsessive-Compulsive DisorderPMA - Pre-Market ApprovalPTSD - Post-Traumatic Stress DisorderSBIR - Small Business Innovation ResearchSCS - Spinal Cord StimulationSDK - Software Development KitSTTR - Small Business Technology TransferTAM - Total Addressable MarketUBC - University of British ColumbiaUK - United KingdomUS - United StatesVC - Venture CapitalVR - Virtual RealityXR - Extended Reality


    Mehr anzeigen Weniger anzeigen
    38 Min.
  • (Part 1) The Neural Implant & BCI Industry Landscape
    Jul 1 2026

    In this episode we analyze the Industry Landscape of healthcare Neural Implants and go over:

    1. The Industry Overview
    2. The Technology Landscape
    3. The Major Players - Top Three
    4. Operational Realities
    5. Competitive Dynamics & How to Win
    6. Building an Ecosystem
    7. The Global Picture

    -------------------------------------------------------------

    Additional Notes and References:

    For current up-to-date figures and TAM, look up https://www.insightaceanalytic.com/report/neurotech-devices-market/3472

    • DBS history (late 1980s) → Sourced from The Lancet Neurology, ScienceDirect, and Frontiers in Neurology
    • FDA approvals (essential tremor 1997, Parkinson's 2002) → Sourced from Liv Hospital timeline and PubMed
    • Medtronic Percept PC / BrainSense adaptive DBS → Official Medtronic press release (FDA approval Feb 24 2025) + APDA + Frontiers in Neurology
    • Nevro high-frequency SCS outperforming conventional devices → SENZA-RCT 24-month data (PMC), Medscape, Nevro PR Newswire
    • EU MDR came into effect 2021, raised compliance burden → TÜV SÜD, Hogan Lovells, PubMed
    • InteraXon / Muse headband (Toronto) → Wikipedia, LinkedIn company page
    • BrainCo classroom EEG deployments in China → Rappler, Big Think, EdSurge, Neurofounders

    Knowledge base (well-documentedpublic record):Cochlear, Abbott, Boston Scientific revenuesegments; BrainGate history; FDA Breakthrough Device program; NIH BRAINInitiative; DARPA programs; EU MDR; Meta/Ctrl-Labs acquisition; Canadianfunding programs

    -------------------------------------------------------------Acronyms:

    ADHD - Attention Deficit Hyperactivity DisorderAI - Artificial IntelligenceALS - Amyotrophic Lateral SclerosisAR - Augmented RealityASIC - Application-Specific Integrated CircuitBCI - Brain-Computer InterfaceBMBF - Bundesministerium für Bildung und ForschungBRAIN - Brain Research Through Advancing Innovative NeurotechnologiesCE - Conformité EuropéenneCIHR - Canadian Institutes of Health ResearchCMS - Centers for Medicare & Medicaid ServicesCOVID - Coronavirus DiseaseDARPA - Defense Advanced Research Projects AgencyDBS - Deep Brain StimulationEEG - ElectroencephalographyEHR - Electronic Health RecordEMG - ElectromyographyEPFL - École Polytechnique Fédérale de LausanneEU - European UnionFDA - Food and Drug AdministrationGDPR - General Data Protection RegulationIDE - Investigational Device ExemptionIP - Intellectual PropertyISO - International Organization for StandardizationITMO - Institute of Technology, Mechanics and OpticsMDR - Medical Device RegulationMS - Multiple SclerosisNIH - National Institutes of HealthNMPA - National Medical Products AdministrationNSERC - Natural Sciences and Engineering Research Council of CanadaNSF - National Science FoundationOCD - Obsessive-Compulsive DisorderPMA - Pre-Market ApprovalPTSD - Post-Traumatic Stress DisorderSBIR - Small Business Innovation ResearchSCS - Spinal Cord StimulationSDK - Software Development KitSTTR - Small Business Technology TransferTAM - Total Addressable MarketUBC - University of British ColumbiaUK - United KingdomUS - United StatesVC - Venture CapitalVR - Virtual RealityXR - Extended Reality

    Mehr anzeigen Weniger anzeigen
    21 Min.
  • From the Operating Room to the Algorithm: The Future of Treating Depression and Anxiety
    Jun 28 2026
    The Neurotechnology of Mental Health.Anxiety and depression usually get framed as emotional experiences. This episode argues they're also disorders of brain circuitry, and that reframing opens the door to treating them with medical technology, not just therapy and medication.We walk through the full spectrum. Invasive options like Deep Brain Stimulation and Vagus Nerve Stimulation, reserved for severe, treatment-resistant cases. Non-invasive technologies already in clinical use today. And where AI changes the equation entirely.We also get into what this could look like in practice, from wearable neuromodulation devices to environments that respond automatically to detected stress.For executives and leaders thinking about where healthtech, AI, and human wellbeing intersect, this episode closes with two questions worth sitting with: what it means to give people tools that regulate their own emotional states, and whether that builds self-awareness or dependence.REFERENCES:SUMMARY OF SAFETY AND EFFECTIVENESS DATAhttps://www.accessdata.fda.gov/cdrh_docs/pdf23/P230024B.pdf| Depression in adults: treatment and management | Guidance https://www.nice.org.uk/guidance/ng222/chapter/Recommendations| Generalised anxiety disorder and panic disorder in adults: https://www.nice.org.uk/guidance/cg113/chapter/RecommendationCDRH Humanitarian Device Exemptionshttps://www.fda.gov/medical-devices/hde-approvals/listing-cdrh-humanitarian-device-exemptionsGetting a Humanitarian Use Device to Markethttps://www.fda.gov/medical-devices/humanitarian-device-exemption/getting-humanitarian-use-device-marketFDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorderhttps://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorderhttps://www.accessdata.fda.gov/cdrh_docs/pdf23/P230024A.pdfEffect of transcutaneous vagus nerve stimulation with electrical stimulation on generalized anxiety disorder: Study protocol for an assessor-participant blinded, randomized sham-controlled trial - PubMedhttps://pubmed.ncbi.nlm.nih.gov/40041000/Ethics and governance of artificial intelligence for healthhttps://www.who.int/publications/i/item/9789240029200Cingulotomy for Intractable Obsessive-compulsive Disorderhttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/497081Potential optimization of focused ultrasound capsulotomy for obsessive compulsive disorderhttps://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awab232/6305828Transcranial focused ultrasound of the amygdala modulates fear network activation and connectivityhttps://pubmed.ncbi.nlm.nih.gov/38447773/Vagus Nerve Stimulation (VNS) for Treatment Resistant Depression (TRD)https://www.cms.gov/medicare/coverage/evidence/vagus-nerve-stimulationTranscutaneous vagus nerve stimulation reduces spontaneous but not induced negative thought intrusions in high worriers https://www.sciencedirect.com/science/article/abs/pii/S0301051118302321Improvement in mood symptoms ​after post-bariatric surgery among people with obesityhttps://pubmed.ncbi.nlm.nih.gov/33891377/Psychiatric and Cognitive Functioning After Metabolic and Bariatric Surgeryhttps://pubmed.ncbi.nlm.nih.gov/40545266/Closed-loop neuromodulation in an individual with treatment-resistant depressionhttps://pubmed.ncbi.nlm.nih.gov/34608328/NHS Identity Guidelineshttps://www.england.nhs.uk/nhsidentity/identity-guidelines/tone-of-voice/Content design: planning, writing and managing contenthttps://www.gov.uk/guidance/content-design/writing-for-gov-uk
    Mehr anzeigen Weniger anzeigen
    13 Min.
  • Centralized or Distributed? The Real AI Org Design Decision
    Jun 22 2026

    Centralized or Distributed? The Real AI Org Design Decision

    Every growing organization eventually faces the same question: should AI capability live in one central team, or spread across the business units that need it?

    In this episode, we walk through how that decision actually plays out as companies scale, and why the "right" answer shifts the moment headcount and complexity grow. We cover the case for a concentrated central team, the operational efficiency and cost trade-offs leadership actually cares about, and the often-overlooked MLOps question: should that function be team-agnostic, or aligned to specific domains?

    We also name a dynamic most org charts don't account for: what happens when a business unit gets tired of waiting on a central team and starts solving its own AI problems independently. That's a structural decision with real political consequences inside the company.

    From there we turn to healthcare to make a different point: domain experts can't just be looped in for review at the end. If clinicians and frontline staff aren't actively involved in building the model, not just validating it after the fact, the result is a tool that doesn't fit how people actually work. Operationalizing it just creates burnout instead of value.

    This conversation is for CEOs, VPs, and directors actively wrestling with how to structure AI and data capability inside their own organizations, closing with a set of questions designed to apply directly to your own org's reality.


    [1] Multiple industry sources report AI-powered recruitment tools can reduce time-to-hire by 30% or more. See: DemandSage, “AI Recruitment Statistics 2026,” demandsage.com; McKinsey-cited data reported in JobsPikr, “AI Recruitment in 2025,” jobspikr.com; SHRM, “The Evolving Role of AI in Recruitment and Retention,” shrm.org. Note: figures vary by implementation; the 30% figure represents a commonly cited benchmark, not a guaranteed outcome.

    [2] Centers for Disease Control and Prevention (CDC), “Health Workers Face a Mental Health Crisis,” Vital Signs, October 2023. Available at: cdc.gov/vitalsigns/health-worker-mental-health. Reports 46% of health workers felt burned out often or very often in 2022, vs. 32% in 2018.

    [3] Mayo Clinic Well-Being Index, 2023–2024 State of Well-Being Report. Reported in HealthLeaders Media, “Where Burnout Rates Are Trending Among Healthcare Professions,” January 2025. Available at: healthleadersmedia.com. Reports 50% of healthcare workers reported burnout in 2023, with nurses at 52% and physicians at 51%.

    [4] Wang, Z. et al. (2021). “A Machine Learning Model for Accurate Prediction of Sepsis in ICU Patients.” Frontiers in Medicine, PMC8553999. Reports AUC of 0.91, sensitivity of 87%, specificity of 89% in external validation. See also: Awad, A. et al. (2025). “Artificial Intelligence-Based Predictive Modeling for Early Sepsis Detection: A Systematic Review.” Critical Care Explorations, PMC12685403. Across 52 studies, AUC range of 0.79–0.96.

    [5] Verhage, T.L. et al. (2024). “To warrant clinical adoption AI models require a multi-faceted implementation evaluation.” npj Digital Medicine. doi:10.1038/s41746-024-01064-1. Notes fewer than 2% of AI models progress beyond prototyping, and that high statistical accuracy in sepsis ICU tools does not translate to clinical adoption.

    [6] Mohr, D.C. et al. (2025). “Adoption of Artificial Intelligence in Healthcare: Survey of Health System Priorities, Successes, and Challenges.” Journal of the American Medical Informatics Association, PMC12202002. Survey of 43 US health systems; clinician alert fatigue and AI tool immaturity identified as leading barriers to adoption, including for sepsis prediction tools.

    Mehr anzeigen Weniger anzeigen
    33 Min.
  • The Middle-Management AI Crisis: Who Gets to Lead, Who Gets Left Behind
    Jun 19 2026

    Middle managers have quietly become one of the most anxious groups in today's workplace, and this episode tackles why head-on. The host opens with a direct question: is AI actually eliminating middle management, or is it exposing a structural problem organizations have ignored for decades?

    The episode traces the role's history, from pre-1990s information pipelines, through the IT revolution (which didn't shrink headcount but did raise expectations), to today's AI moment. It names exactly what AI threatens: the synthesis-and-coordination work that defined the job, reports, summaries, status updates. But it argues this exposes what was always irreplaceable: emotional intelligence and conflict resolution, now the core competency for execution.

    Using a "weakest link" framing, the host shows how this plays out differently by industry: manufacturing managers freed from traffic-cop duties to become business bridges; consulting leads protected by client relationships but at risk of becoming pure administrators; SaaS managers becoming "AI orchestrators" who decide what to trust rather than doing synthesis themselves; and healthcare/neurotech managers carrying moral accountability AI can't touch.

    The back half turns prescriptive: organizations need to redistribute high-value work, formalize neglected secondary relationships, build in time for improvement, and (critically) redefine what managers are measured on, since rewarding throughput just optimizes away the judgment work that matters.

    It closes with practical advice for managers (build contextual judgment, become a bridge not a bottleneck, develop your team, get fluent with AI as a collaborator) and three reflective listener questions about where their own value really sits.

    References:

    • Leavitt, H. J., & Whisler, T. L. (1958). "Management in the 1980s." Harvard Business Review, 36(6), 41–48.
    • Dopson, S., & Stewart, R. (1993). "Information Technology, Organisational Restructuring and the Future of Middle Management." New Technology, Work and Employment, 8(1), 10–20.
    • Netflix Inc.'s Organizational Structure & Its Strategic Implications — Rancord Society. https://www.rancord.org/netflix-organizational-structure-design-organizational-chart-characteristics
    • Spotify Organizational Structure — FourWeekMBA. https://fourweekmba.com/spotify-organizational-structure/
    • "Project Oxygen: The 8 Essential Qualities of Effective Managers" — CliffsNotes. https://www.cliffsnotes.com/study-notes/20870159
    • "Effective Engineering Managers: The 10 traits that make great managers from Google's Project Oxygen" — Addy Osmani. https://addyo.substack.com/p/effective-engineering-managers
    • Goldratt, E. M. — Theory of Constraints (overview). "No Chain Stronger Than Its Weakest Link: Constraints Theory" — IncrementOne. https://www.incrementone.com/perspectives/no-chain-can-ever-be-stronger-than-its-weakest-link-the-theory-of-constraints
    • "Why Middle Management will Fall First in the AI Revolution" (Pega survey, 78% of executives) — Chris Hood. https://chrishood.com/why-middle-management-will-fall-first-in-the-ai-revolution/
    • "Middle managers are getting laid off—but their role is 'more important than ever'" (Gartner, Oct. 2024 report) — CNBC. https://www.cnbc.com/2025/12/29/middle-managers-are-getting-laid-offbut-their-role-is-more-important-than-ever-says-leadership-expert.html
    Mehr anzeigen Weniger anzeigen
    20 Min.
  • Your Brain is Changing With or Without You: The Convergence of Neurotech, Brain-Computer Interfaces, AI, Psychedelics, and Mental Health
    Jun 18 2026

    What happens when psychedelics, neurotechnology, AI, brain-computer interfaces, and even ancient healing practices like Reiki begin converging into a single ecosystem?

    In this thought-provoking episode, we explore how neuroscience and artificial intelligence are reshaping our understanding of the human brain and what that means for mental health, healing, performance, and the future of human potential. From Neuralink and brain-computer interfaces to psilocybin therapy, optogenetics, neurofeedback, and emerging cognitive enhancement technologies, we examine the breakthroughs that are moving from research labs into real-world applications.

    We also discuss the opportunities and challenges facing practitioners, healthcare innovators, investors, regulators, and everyday people as these technologies evolve. Can AI help personalize mental health treatment? Could neurotechnology validate practices like Reiki? Who should own neural data? And are we prepared for a future where enhancing cognition becomes as common as treating disease?

    Whether you're interested in neuroscience, mental health, emerging technology, consciousness, or the future of healthcare, this episode offers a comprehensive look at one of the most important convergences of our time.

    Key References & Further Reading:

    Boyden ES et al. (2005). Millisecond-timescale,genetically targeted optical control of neural activity. Nature Neuroscience8(9):1263-1268.

    MIT Synthetic Neurobiology Group — OptogeneticsProjects: synthneuro.org/projects

    Willett FR et al. (2021). High-performancebrain-to-text communication via handwriting. Nature 593:249–254.

    Carhart-Harris R et al. (2021). Trial of psilocybinversus escitalopram for depression. NEJM 384:1402-1411.

    Hampson RE et al. (2018). Facilitation of memoryencoding in humans via a closed-loop cortical neuroprosthetic. JNE 15(3).

    Grand View Research (2024). Neurotechnology MarketSize, Share & Trends Analysis Report.

    Sahel JA et al. (2021). Partial recovery of visualfunction in a blind patient after optogenetic therapy. Nature Medicine27:1223-1229.

    Iaccarino HF et al. (2016). Gamma frequency entrainmentattenuates amyloid load and modifies microglia. Nature 540:230–235.

    "Beyond the Breakthrough Therapy designations forpsilocybin (COMPASS Pathways and USONA Institute, 2018 to 2019) and MDMA-assisted therapy for PTSD" (MAPS, 2017)

    Mehr anzeigen Weniger anzeigen
    34 Min.